A retrospective study analysing clinical outcomes of mutated lung cancer patients after resistance to osimertinib
Latest Information Update: 04 Mar 2021
At a glance
- Drugs Brigatinib (Primary) ; Cabozantinib (Primary) ; Cetuximab (Primary) ; Erlotinib (Primary) ; Gefitinib (Primary) ; Osimertinib (Primary) ; Platinum complexes
- Indications Adenocarcinoma; Lung cancer
- Focus Therapeutic Use
- 04 Mar 2021 New trial record
- 31 Jan 2021 Results presented at the 2020 World Conference on Lung Cancer